Literature DB >> 14747693

Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells.

Eunok Im1, Jesse D Martinez.   

Abstract

Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is known as a cytoprotective agent. UDCA prevents apoptosis induced by a variety of stress stimuli including cytotoxic bile acids such as deoxycholic acid (DCA). Here we examined the molecular mechanism by which UDCA can antagonize DCA-induced apoptosis in human colon cancer cells. UDCA pretreatment decreases the number of apoptotic cells caused by exposure to DCA and UDCA. Further studies of the signaling pathway showed that UDCA pretreatment suppressed DNA binding activity of activator protein-1 and this was accompanied by downregulation of both extracellular signal-regulated kinase (ERK) and Raf-1 kinase activities stimulated by exposure to DCA. DCA was also found to activate epidermal growth factor receptor (EGFR) activity and UDCA inhibited this. Collectively, these findings suggest that the inhibitory effect of UDCA in DCA-induced apoptosis is partly mediated by modulation of EGFR/Raf-1/ERK signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747693     DOI: 10.1093/jn/134.2.483

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  49 in total

1.  Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis.

Authors:  Jasleen Shant; Kunrong Cheng; Bernard S Marasa; Jian-Ying Wang; Jean-Pierre Raufman
Journal:  Exp Cell Res       Date:  2008-11-20       Impact factor: 3.905

2.  Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects.

Authors:  Ali Siddiqui; Sheila Rodriguez-Stanley; Sattar Zubaidi; Philip B Miner
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 3.  Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer.

Authors:  Sara M Centuori; Jesse D Martinez
Journal:  Dig Dis Sci       Date:  2014-06-11       Impact factor: 3.199

4.  Deoxycholic acid mediates non-canonical EGFR-MAPK activation through the induction of calcium signaling in colon cancer cells.

Authors:  Sara M Centuori; Cecil J Gomes; Jesse Trujillo; Jamie Borg; Joshua Brownlee; Charles W Putnam; Jesse D Martinez
Journal:  Biochim Biophys Acta       Date:  2016-04-13

5.  Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis.

Authors:  Betsy C Wertheim; Jeffrey W Smith; Changming Fang; David S Alberts; Peter Lance; Patricia A Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2011-11-04

6.  Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2.

Authors:  Urszula Dougherty; Dario Cerasi; Ieva Taylor; Masha Kocherginsky; Ummuhan Tekin; Shamiram Badal; Lata Aluri; Amikar Sehdev; Sonia Cerda; Reba Mustafi; Jorge Delgado; Loren Joseph; Hongyan Zhu; John Hart; David Threadgill; Alessandro Fichera; Marc Bissonnette
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

7.  Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.

Authors:  Patricia A Thompson; Betsy C Wertheim; Denise J Roe; Erin L Ashbeck; Elizabeth T Jacobs; Peter Lance; María Elena Martínez; David S Alberts
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-01

8.  Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR.

Authors:  Rebecca Feldman; Jesse D Martinez
Journal:  Biochim Biophys Acta       Date:  2009-05-13

9.  Bile acids as endogenous etiologic agents in gastrointestinal cancer.

Authors:  Harris Bernstein; Carol Bernstein; Claire M Payne; Katerina Dvorak
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

Review 10.  A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Authors:  Elizabeth C Goode; Simon M Rushbrook
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.